LongevityResearch Phase

FOXO4-DRI

Subcutaneous injection, Intravenous

Overview

A D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. In senescent cells, FOXO4 sequesters p53 away from mitochondria, preventing p53-mediated apoptosis and enabling senescent cell survival.

Mechanism of Action

FOXO4-DRI competitively binds p53, releasing it to trigger selective apoptosis of senescent cells while sparing healthy cells, functioning as a senolytic agent..

Research Summary & Key Findings

In vivo studies in naturally aged and fast-aging (XpdTTD/TTD) mice demonstrated restoration of fitness, fur density, and renal function after FOXO4-DRI treatment (Baar et al., Cell, 2017). Selectively induced apoptosis in senescent cells in vitro without affecting proliferating or quiescent cells. Preclinical stage with no human clinical trials initiated. The D-retro-inverso design confers protease resistance for improved in vivo stability.

Clinical Status

Research Phase

FOXO4-DRI is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injectionIntravenous

Related Peptides in Longevity

Epithalon (Epitalon)

Research Phase

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural epithalamin peptide produced by the pineal gland. Epitha...

View details

MOTS-c

Research Phase

A mitochondrial-derived peptide encoded by the 12S rRNA gene of mitochondrial DNA. MOTS-c is a 16-amino acid peptide tha...

View details

Humanin

Research Phase

A 24-amino acid mitochondrial-derived peptide encoded within the 16S rRNA region of mitochondrial DNA. Humanin exerts cy...

View details

NAD+ Precursors (NMN)

In Clinical Trials

Nicotinamide mononucleotide (NMN) is a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), a coen...

View details

Find a Provider

Find a verified provider who offers FOXO4-DRI therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply FOXO4-DRI.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.